Kategorije za Uncategorized

package insert

ePI vs traditional package insert: pros and cons of the electronic leaflet and package leaflet

July 24, 2026 10:27 am Published by

The pharmaceutical industry is entering one of the most significant changes in product information management in decades. While the traditional package leaflet remains a regulatory requirement, companies are now preparing for the gradual introduction of the electronic leaflet through the European Medicines Agency’s electronic product information (ePI) initiative. This transition is now anchored in the... View Article

veterinary signal detection

Which firms handle signal detection for veterinary drugs? A guide to veterinary signal detection services

July 23, 2026 1:18 pm Published by

Keeping veterinary medicines safe after they reach the market is not simply a regulatory expectation—it is an ongoing responsibility. Under EU veterinary pharmacovigilance legislation, marketing authorisation holders (MAHs) must continuously monitor the safety of their products, identify emerging risks, and take appropriate action whenever new safety concerns arise. At the centre of this process is... View Article

patient journey mapping

Patient journey mapping services for oncology: Find the right strategic partner

July 23, 2026 8:39 am Published by

Despite major advances in cancer diagnosis and treatment, many oncology patients still experience fragmented care, delayed diagnoses, limited access to therapies, inconsistent education, and challenging transitions between healthcare providers. Every delay, communication gap, or missed intervention can negatively affect treatment outcomes, patient experience, and adherence. For pharmaceutical companies, these challenges also make it more difficult... View Article

veterinary safety case management

Veterinary safety case management: how to choose the right end-to-end vet safety case management vendors

July 9, 2026 9:46 am Published by

Modern veterinary safety case management is no longer just an operational pharmacovigilance activity—it is a business-critical function that directly affects regulatory compliance, product safety, and market confidence. As veterinary pharmaceutical companies expand into new markets, manage growing product portfolios, and navigate increasingly complex regulatory requirements, the volume and complexity of adverse event reports continue to... View Article

medical education agency

Alternatives to large global med-ed agencies: what to look for in a medical education agency

July 8, 2026 1:30 pm Published by

Pharmaceutical companies invest significant time and resources into medical education, yet many Medical Affairs teams struggle to achieve the impact they expect. Working with large global providers can mean lengthy approval processes, generic educational programmes, limited flexibility, and reduced access to senior scientific experts. As project complexity increases, these challenges can delay delivery, place additional... View Article

medical eduaction consulting

Medical education consulting: how to choose the right partner for pharmaceutical success

July 2, 2026 10:56 am Published by

The expectations placed on pharmaceutical companies to deliver high-quality, scientifically accurate, and compliant medical education have never been higher. Healthcare professionals expect relevant, evidence-based educational content, while regulators require that all scientific communication remains balanced, accurate, and aligned with applicable standards. At the same time, Medical Affairs teams are often expected to deliver increasingly complex educational programmes with limited internal resources,... View Article

signal detection process in pharmacovigilance

Signal detection process in pharmacovigilance and risk management in pharmacovigilance: how to choose the right vendor

July 1, 2026 10:17 am Published by

Pharmaceutical companies today face increasing pressure to maintain continuous oversight of product safety while meeting ever-evolving global regulatory expectations. A robust signal detection process in pharmacovigilance is no longer limited to reviewing individual case reports—it requires the ability to identify, validate, assess, and act on emerging safety signals using data from multiple sources throughout the... View Article

Patient journey optimization

Market access vs. patient journey optimization: which should come first?

June 23, 2026 2:02 pm Published by

Patient journey optimization is rapidly becoming one of the most important strategic priorities for pharmaceutical companies. While many organizations continue to focus primarily on market access, reimbursement, and product availability, they often overlook a critical reality: patients do not experience healthcare through market access pathways. They experience it through diagnosis delays, fragmented care, treatment decisions,... View Article

patient journey pharma

Alternatives to big pharma consulting firms for patient journey pharma projects

June 17, 2026 9:45 am Published by

Pharmaceutical companies are investing heavily in patient-centricity, yet many still struggle to achieve measurable improvements in patient outcomes. The reason is often surprisingly simple: they do not fully understand the patient journey pharma landscape. Critical barriers to diagnosis, treatment initiation, adherence, and long-term disease management frequently remain hidden, making it difficult to identify where interventions... View Article

clinical evaluation of medical devices

Why choosing the right partner for clinical evaluation of medical devices matters

June 4, 2026 8:41 am Published by

Your medical device is ready for the market. The development phase is complete, the technical documentation is progressing, and your team expects the CE marking process to move forward smoothly. Then comes the most challenging part: clinical evaluation of medical devices. Many manufacturers underestimate how demanding MDR clinical evaluation has become. A weak literature review,... View Article